M1 Kliniken AG reported substantial financial growth for the first nine months of 2025, with EBIT increasing by 11% to EUR 24.5 million compared to EUR 22.1 million in the same period last year. The company achieved earnings per share of EUR 0.86, up from EUR 0.77 in the prior year period, reflecting continued profitability and operational efficiency. This performance underscores the company's successful execution of its strategic initiatives in the competitive medical aesthetics market.
Group revenue grew by 6.7% to EUR 274.3 million, up from EUR 257.2 million in the first nine months of 2024. The company's EBITDA showed strong improvement, increasing by 9% to EUR 28.2 million from EUR 25.9 million in the comparable period. The EBIT margin expanded to 8.9% from 8.6%, indicating improved operational efficiency across the organization. These financial metrics demonstrate the company's ability to maintain growth momentum while enhancing profitability through strategic management.
The Beauty segment emerged as the primary growth driver, with revenue increasing by 9.5% to EUR 77.8 million and EBIT surging by 29.7% to EUR 21.1 million. The segment's EBIT margin improved significantly to 27.1% from 22.9% in the prior year period. This remarkable performance was attributed to efficiency gains through optimized processes and higher utilization of medical capacities. The company's targeted pricing strategy successfully attracted new customer groups while maintaining margin quality, supporting market share expansion without compromising profitability.
Meanwhile, the Trading segment recorded solid revenue growth of 6% to EUR 196.5 million, though EBIT declined by 41.4% to EUR 3.4 million. The company announced that its 85% subsidiary, HAEMATO AG, has signed an agreement to sell its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe's leading healthcare providers based in Mannheim. This transaction, subject to usual antitrust approvals, represents a strategic move to sharpen the company's focus on its core medical aesthetics business.
The company's consistent implementation of efficiency measures and targeted expansion of medical capacities have contributed significantly to improved profits. M1 Kliniken AG is pursuing its strategic course of positioning itself as the world's leading vertically integrated pure-play provider of medical aesthetics. The company plans to continue its profitable growth trajectory by expanding its network of national and international clinics, with expectations of increasing this figure to between EUR 200 million and EUR 300 million by 2029 while maintaining a sustainable EBIT margin of at least 20%.
This financial performance is particularly significant for investors and industry observers as it demonstrates the resilience and growth potential of the medical aesthetics sector. The company's ability to achieve double-digit EBIT growth amid competitive market conditions highlights the effectiveness of its business model and operational strategies. The strategic divestiture of non-core assets while strengthening the Beauty segment positions M1 Kliniken AG for sustained long-term growth in the global medical aesthetics market. The company's focus on establishing M1 Med Beauty as the world's leading brand for aesthetic medicine reflects its commitment to standardization, scalability, and medical excellence across its international operations.
